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Abstract. Aortic valve (AoV) stenosis is the third most 
common cardiovascular disease. The pathogenesis of AoV 
stenosis is associated with an inflammatory process where 
MMPs serve important roles. The aim of the present study was 
to determine the association between matrix metalloprotein-
ases (MMPs), tissue inhibitors of metalloproteinases (TIMPs) 
and inflammatory factors, and AoV stenosis at various degrees 
of severity compared with the control. A total of 18 patients 
with mild, 19 with moderate and 15 with severe AoV stenosis 
were included in the present stud, and 50 individuals were 
enrolled in the control group. The severity of stenosis was 
determined by echocardiography. The expression levels of 
chemerin, fibroblast growth factor 21, MMP-1, -3, and -9, 
and TIMP‑1 and ‑3 were analyzed by ELISA. Data were 
analyzed using GraphPad Prism7 software. The expression 
levels of MMP-1 was increased in patients with stenosis 
compared with the control group (P=0.0043). Distribution 
of the trimodal MMP-1 values was obtained in the stenosis 
group and monomodal in the control group. A total of 80% of 
patients in the stenosis group presented significantly increased 
expression levels of MMP-1 compared with the control group 
(P=0.0002). Expression of MMP‑1 was significantly higher 
in all stenosis groups compared with the control. The highest 
expression level of MMP-1 appeared in patients with moderate 
stenosis (P<0.0001). There was no significant difference in 
the expression of MMP-3, MMP-9 and TIMP-1 in the aortic 
stenosis group, compared with the control group. A positive 
correlation between MMP-1 and MMP-9 expression levels 
was identified (r=0.37; P=0.017). The increase of MMP‑1 was 
correlated with the increase of MMP-9, but not with the level 
of MMP‑3. The expression levels of chemerin was significantly 
elevated in patients with stenosis compared with healthy 
patients. The highest expression levels of chemerin were 
determined in patients with mild (P=0.0001) and moderate 
(P=0.0007) stenosis and decreased with the grade of severity 
compared with the control group. The expression of FGF‑21 
was significantly different between the control and mild 
(P=0.013), moderate (P=0.015) and severe stenosis (P=0.003) 
groups. The expression levels of FGF‑21 increased with the 
increase in severity grade, reaching the maximum for severe 
stenosis. The results of the present study indicated that the 
inflammatory process is predominantly occurring at the early, 
mild stage of stenosis and the most prominent extracellular 
matrix remodeling occurs in moderate stenosis (demonstrated 
by MMP‑1 levels). In patients with severe stenosis, the levels 
of MMP-1 and chemerin (which are lower than in a case of 
mild or moderate stenosis) could indicate the development of 
calcinosis and the reduction in activity or inactivation of the 
inflammatory process.
Introduction
Acquired calcific aortic valve (AoV) stenosis is the most common 
valvular disease in the USA and Europe and is the second most 
frequent cause for cardiac surgery (1). The prevalence of aortic 
valve stenosis is 0.2% among adults aged 50‑59 years, 1.3% 
among patients aged 60‑69 years, and ≤9.8% among patients 
aged 80‑89 years (2).
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Overall, AoV stenosis is present in 2.6% of adults >75 years 
of age (3). The average time from diagnosis of aortic sclerosis 
to the development of moderate and severe AoV stenosis is 
6 and 8 years, respectively (4).
Among symptomatic patients with medically treated 
moderate‑to‑severe aortic stenosis, mortality from the onset 
of symptoms is ~25% at 1 year and 50% at 2 years (5). 
Symptoms of aortic stenosis usually develop gradually after 
an asymptomatic latent period of 10‑20 years (6).
AoV stenosis has been previously considered to be the 
cause of aging and atherosclerosis; however, in recent years 
this view has changed. At present, AoV stenosis is considered 
to be an active process. Inflammatory factors, extracellular 
matrix remodeling and calcification processes serve important 
roles in the pathogenesis of AoV stenosis (7).
Calcific AoV stenosis is characterized by cell proliferation 
and development of remodeling processes in the extracellular 
matrix. Matrix metalloproteinases (MMPs) serve important 
roles in the remodeling processes, which leads to the degrada-
tion of the extracellular matrix (8‑10).
MMPs are some of the most frequently studied extracellular 
matrix proteins in the pathogenesis of calcific AoV stenosis (11). 
MMPs are zinc‑dependent endopeptidases (collagenases, gelati-
nases and stromelysins) that serve roles in both physiological and 
pathological remodeling of the extracellular matrix in a number 
of tissues and diseases (12). Tissue remodeling is affected by the 
local balance between MMPs and endogenous tissue inhibitors 
of metalloproteinases (TIMPs) (13,14). The present study deter-
mined the expression levels of MMP-1, -3 and -9 in the blood 
serum and the corresponding TIMP-1 and -3 expression. These 
MMPs, in particular MMP-1 and MMP-9, have been described 
by numerous researchers who have investigated their possible 
association with stenosis (12,13,15,16). However, mainly as a 
material using tissues, removed during the aortic valve replace-
ment surgery, consequently, these studies cannot compare the 
changes between severity degrees of aortic valve stenosis. The 
number of histological materials included in these previous 
studies was frequently small and there were ethical restrictions 
associated with the establishment of appropriate control groups.
The current study aimed to clarify the factors that serve 
an active role in the development of AoV stenosis, and to 
determine their presence and significance by determining their 
serum levels in patients with aortic valve stenosis of different 
severity degrees in comparison with the control group. This 
method was used to estimate the sequence of processes 
occurring during the development of aortic valve stenosis.
C‑reactive protein is known as a stable inflammatory factor 
and a marker of inflammation, and chemerin is a relatively 
new biomarker involved in various inflammatory processes. 
Chemerin has been previously demonstrated to be released by 
fibroblasts in the heart (17). FGF‑21, that has been described 
as a factor with a broad spectrum of manifestations, may serve 
a cardioprotective role, and may contribute to the development 
of fibrosis and may be excreted by cardiac cells (18‑21).
The aim of the present study was to demonstrate the 
involvement of inflammatory factors and MMPs in the devel-
opment of aortic valve stenosis, their role in progression of 
the disease according to the AoV stenosis severity grades, and, 
therefore indirectly provide evidence of the possible sequence 
and mechanism of the development of AoV stenosis.
Patients and methods
Study population. The current study was conducted from 
January 2013 until the end of December 2016 at the Vidzeme 
Regional Hospital (Valmiera, Latvia), P. Stradins Clinical 
University Hospital (Riga, Latvia) and at the polyclinic‑ 
Zemgale Health Centre (Jelgava, Latvia). The study protocol 
was approved by the Riga Stradins University Ethics 
Committee on Research on Humans and the study protocol 
conforms to the Ethical Guidelines of the 1975 Declaration 
of Helsinki. A total of 102 patients were selected according 
to inclusion and exclusion criteria and divided in two core 
groups, an AoV stenosis group and a control group. The 
control group included patients without AoV stenosis, aged 
55‑80 years, which matched the average age of patients with 
AoV stenosis according to the Guidelines on the Management 
of Valvular Heart Disease 2012 of the European Society of 
Cardiology (22). Written informed consent was obtained 
from each patient enrolled in the current study. Patients were 
included in the control group according to echocardiographi-
cally confirmed results of a healthy aortic valve. Exclusion 
criteria in both groups included: Obesity, systemic connective 
tissue diseases, infectious diseases, oncological diseases, 
diabetes, thyroid dysfunction, moderate, severe and uncon-
trolled arterial hypertension, with acute coronary syndrome 
in anamnesis and coronary heart disease, left ventricular 
systolic dysfunction with reduced ejection fraction below 40%, 
cerebral infarction, transient ischemic attack, echocardio-
graphically confirmed cardiomyopathy and pathology of other 
valves. Exclusion criteria in the AoV stenosis group included 
congenital and rheumatic aortic valve stenosis.
Aortic valve stenosis assessment. All patients were examined 
echocardiographically and the data were obtained using 
GE VIVID 7 Dimension Cardiovascular Ultrasound system 
(GE Healthcare; GE Healthcare, Chicago, IL, USA) and Philips 
iE 33 Ultrasound Machine (Philips Healthcare, Amsterdam, 
The Netherlands). Each echocardiography examination was 
evaluated by 2 professionals. Patients with AoV stenosis were 
subdivided into three groups depending on the severity grade 
according to the echocardiography criteria, including aortic jet 
velocity [Vmax (m/s)], mean pressure gradient [PG (mmHg)], 
aortic valve area [AVA (cm2)] and indexed AVA (cm2/m2). The 
following groups were established: i) Severe (Vmax >4 m/sec; 
PG >40 mmHg; AVA <1.0 cm2; indexed AVA <0.6); ii) moderate 
(Vmax 3.0‑4.0 m/sec; PG 20‑40 mmHg; AVA 1.0‑1.5 cm2; 
indexed AVA 0.60‑0.85); and iii) mild (Vmax 2.5‑2.9 m/sec; 
PG <20 mmHg; AVA >1.5 cm2; indexed AVA >0.85; Table I).
Biochemical analysis. Venous blood samples were collected 
and serum was obtained in accordance with the serum prepa-
ration instructions (23). Serum samples were stored at ‑80˚C 
and were available for all 102 patients. The concentration 
of lipids and C‑reactive protein were analyzed via standard 
methods at the laboratory of the Pauls Stradins Clinical 
University Hospital (Riga, Latvia). Total cholesterol was 
determined using the commercially available test [ADVIA® 
Chemistry Cholesterol_2 (CHOL_2); cat. no. 10376501], 
Siemens Healthineers, Erlangen, Germany], based on an enzy-
matic method that utilizes cholesterol esterase and cholesterol 
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oxidase conversion, followed by a Trinder endpoint (24). The 
cholesterol esters were hydrolyzed by cholesterol esterase to 
form cholesterol and free fatty acids. The cholesterol was then 
converted to cholest‑4‑en‑3‑one by cholesterol oxidase in the 
presence of oxygen to form hydrogen peroxide. A colored 
complex was then formed from hydrogen peroxide, 4‑aminoan-
tipyrine and phenol under the catalytic influence of peroxidase. 
The absorbance of the complex was measured as an endpoint 
reaction at 505/694 nm. Triglycerides were determined 
using commercially the available test [ADVIA® Chemistry 
Triglycerides_2 (TRIG_2) Reagent; cat. no. REF 10335892]; 
Siemens Healthineers], based on the Fossati three‑step enzy-
matic reaction with a Trinder endpoint. The single-reagent 
procedure quantitates the total triglycerides including the 
monoglycerides, diglycerides and free glycerol fractions. The 
triglycerides were converted to glycerol and free fatty acids 
by lipase. Glycerol was then converted to glycerol‑3‑phos-
phate by glycerol kinase, which was further converted with 
glycerol‑3‑phosphate‑oxidase to form hydrogen peroxide. 
A colored complex was formed from hydrogen peroxide, 
4‑aminophenazone and 4‑chlorophenol under the catalytic 
influence of peroxidase. The absorbance of the complex was 
measured as an endpoint reaction at 505/694 nm. High‑density 
lipoprotein cholesterol and low‑density lipoprotein cholesterol 
were determined using commercially available tests [ADVIA® 
Chemistry Direct HDL Cholesterol (D‑HDL) Reagent; 
cat. no. 07511947 and ADVIA® Chemistry LDL Cholesterol 
Direct (DLDL) Reagent; cat. no. 09796248 respectively]; 
Siemens Healthcare Diagnostics Inc., Tarrytown, USA], using 
the direct method. Direct high‑density lipoprotein cholesterol 
method measured HDL cholesterol in serum without prior 
separation, based on procedures developed by Izawa et al (25). 
Cholesterol from non-HDL particles was released and 
eliminated in the first step of the reaction. Cholesterol in HDL 
particles was further released in the second step by detergent 
in Reagent 2 [component of the ADVIA® Chemistry Direct 
HDL Cholesterol (D‑HDL) kit] and the HDL cholesterol was 
measured via a Trinder reaction. The low‑density lipoprotein 
cholesterol direct method measured LDL cholesterol in serum. 
The first step of the reaction eliminated cholesterol associated 
with lipoproteins other than low‑density lipoprotein. A selec-
tive surfactant [component of the ADVIA® Chemistry LDL 
Cholesterol Direct (DLDL) kit] released cholesterol preferen-
tially from non‑LDL particles. Hydrogen peroxide produced by 
cholesterol esterase and cholesterol oxidase in the first step was 
then eliminated by catalase. Another surfactant in Reagent 2 
[component of the ADVIA® Chemistry LDL Cholesterol Direct 
(DLDL) kit] released cholesterol from the low density lipopro-
tein. Azide in R2 inhibited the catalase. Hydrogen peroxide 
generated by cholesterol esterase and cholesterol oxidase was 
then quantified using a Trinder endpoint. All methods were 
performed using the Siemens Advia 1800 analyzer (Siemens 
Healthcare Diagnostics Inc., Tarrytown, NY, USA) in accor-
dance with the manufacturer's protocol. C-reactive protein was 
Table I. Baseline characteristics of the patients.
 Control, AoV mild stenosis, AoV moderate stenosis, AoV severe stenosis,
Characteristic n=50 n=18 n=19 n=15
Sex (%)
  Male 11 (22.0)   2 (11.1)   8 (42.1) 7 (46.7)
  Female 39 (78.0) 16 (88.9) 11 (57.9) 8 (53.3)
Age 65.18 (9.74) 70.53 (6.08) 72.16 (8.20) 65.27 (8.13)
  P=0.127 P=0.012 P>0.999
BMI 26.04 (4,31) 27.39 (3,10) 25.81 (4,58) 27.40 (3,18)
  P=0.399 P=0.682 P=0.869
LDL, mmol/l 3.28 (1.18) 3.05 (0.97) 2.59 (0.92) 3.10 (1.12)
  P>0.999 P=0.057 P>0.999
Triglycerides, mmol/l 1.47 (0.71) 1.64 (0.84) 1.11 (0.56) 1.27 (0.57)
  P=0.406 P=0.178 P=0.406
Total cholesterol, mmol/l 5.49 (1.28) 5.01 (1.34) 4.21 (1.18) 4.68 (1.08)
  P=0.056 P=0.001 P=0.016
CRP, mg/l  0.95 (0.50‑2.55) 3.00 (1.5‑3.70) 1.75 (0.37‑2.97) 1.2 (0.7‑5.00)
  P=0.016 P=0.37 P=0.17
SV, ml 81.86 (20.11) 73.63 (18.92) 77.72 (18.65) 75.93 (15.49)
  P=0.299 P=0.501 P=0.501
EF, % 62.22 (6.35) 57.16 (9.23) 61.78 (8.23) 56.13 (7.84)
  P=0.014 P=0.291 P=0.007
All data are presented as the mean (± standard deviation), with the exception of CRP levels presented as the median and interquartile range. 
All P‑values are vs. the control group. BMI, weight in kilograms divided by the square of the height in meters; LDL, low‑density lipoprotein 
cholesterol; CRP is C‑reactive protein; SV, stroke volume, measured by left ventricular outflow method; EF, ejection fraction, measured by 
Simpson's method.
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determined using the particle enhanced turbidimetric method. 
Human CRP was determined using commercially available 
test where CRP was agglutinated with latex particles coated 
with monoclonal anti‑CRP antibodies (cat. no. CRPLX; Roche 
Diagnostics, Basel, Switzerland). The precipitate is determined 
turbidimetrically at 552 nm. This was performed using the 
Roche Cobas Integra 400 Plus analyzer (Roche Diagnostics), 
according to the manufacturer's protocol. Analyses of MMP‑1, 
MMP‑3, MMP‑9, TIMP‑1, TIMP‑3, chemerin and FGF‑21 
were performed at the biochemical laboratory of the Riga 
Stradins University (Riga, Latvia), using the following ELISA 
kits: Human MMP‑1 (cat. no. EHMMP1; Pierce; Thermo 
Fisher Scientific, Inc., Waltham, MA, USA); human MMP‑3 
(cat. no. ELH‑MMP3; RayBiotech, Inc., Norcross, GA, USA); 
human MMP‑9 (cat. no. KHC3061; Invitrogen; Thermo 
Fisher Scientific, Inc.); human TIMP‑1 (cat. no. ab100651; 
Abcam, Cambridge, UK); human TIMP‑3 (cat. no. ab119608; 
Abcam); human Chemerin ELISA (cat. no. EZHCMRN‑57K; 
Merck KGaA, Darmstadt, Germany) and human FGF‑21 
ELISA (cat. no. EZHFGF21‑19K; Merck Millipore, USA). 
Results were detected using an Infinite 200 PRO multimode 
reader (Tecan Group, Ltd., Mannedorf, Switzerland) and 
Multiskan Ascent microplate reader (Thermo Labsystems, 
Helsinki, Finland). The procedure was performed in accor-
dance with the ELISA kit manufacturer's protocol.
Statistical analysis. All the graphs, calculations, and statistical 
analyses were performed using GraphPad Prism software 
version 7.0 for Mac (GraphPad Software, Inc., La Jolla, CA, 
USA). Comparison of means between different groups was 
performed using one‑way analysis of variance (ANOVA). 
Brown‑Forsythe and Bartlett's tests were applied to determine 
whether the obtained data were normally distributed. In the 
case of unequal standard deviations, comparisons of medians 
between different groups were performed with non-parametric 
one‑way ANOVA on ranks or Kruskal‑Wallis test followed 
by post‑hoc analysis. In all cases two‑stage step‑up method 
of Benjamin, Krieger and Yekutieli was used as post‑hoc 
analysis (26). Baseline statistics are presented in Table I. 
All results for age, body mass index, low‑density lipoprotein 
cholesterol, total cholesterol, triglycerides and ejection fraction 
(measured by Simpson's method), stroke volume (measured 
by left ventricular outflow method) (27) are presented as 
the mean ± standard deviation. Results for high‑sensitivity 
C-reactive protein are presented as the median and inter-
quartile range. As the distribution of data was logarithmic, 
the geometric mean and geometric standard deviation of the 
data were used to represent the results. A two-tailed P<0.05 
was considered to indicate a statistically significant differ-
ence. The correlation analysis method was used to study the 
associations between quantitative variables. Depending on the 
data distribution, parametric (Pearson's) or non-parametric 
(Spearman's) correlation analyses were performed and 
corresponding characteristics (rp or rs) were used.
Results
Patient characteristics. Patient characteristics are presented in 
Table I. A total of 102 patients were included and divided into 
three AoV stenosis severity groups and a control group. A total 
of 18 patients presented mild, 19 moderate, and 15 severe AoV 
stenosis, and there were 50 patients without AoV stenosis in the 
control group. The aforementioned exclusion criteria allowed 
the selection of appropriate study groups. Although the number 
of patients in the subgroups was limited, the statistical analysis 
revealed significant P-values in the range P<0.05-0.0001.
The average age of patients in all of the aortic stenosis 
groups and the control group were similar, and the mean 
level of body mass index did not differ between the groups. 
Triglyceride and low‑density lipoprotein cholesterol mean 
values did not differ significantly between the stenosis groups 
and the control group. The aortic stenosis patient groups were 
similar in respect to the mean values of ejection fraction, 
measured by Simpson's method and stroke volume, measured 
by left ventricular outflow method. However, ejection fraction 
in severe aortic stenosis group was significantly decreased 
(P=0.007) in comparison with the control group. The 
expression of C‑reactive protein was statistically significantly 
higher (P=0.016) among patients with mild stenosis compared 
with the control patients (Fig. 1).
Differences in chemerin expression levels between the patient 
groups. The mean chemerin expression level among all patients 
with AoV stenosis differed significantly (P<0.0001) compared 
with the control group (Fig. 2). A more detailed analysis 
of AoV stenosis subgroups, including mild, moderate and 
severe(Fig. 3), demonstrated that chemerin level was signifi-
cantly elevated in all three AoV stenosis groups compared 
with the control patients and the most pronounced effect was 
observed in the mild AoV stenosis group (P=0.0001).
Chemerin level in the mild AoV stenosis group was also 
significantly higher compared with the severe AoV stenosis 
group (P<0.05), while no significant difference between 
moderate and severe AoV stenosis groups was observed. 
Elevated chemerin levels decreased with the increase of AoV 
stenosis severity, reaching the lowest level in patients with 
severe aortic stenosis (Fig. 3). This effect was confirmed 
by regression analysis, where a linear regression line with a 
negative slope was determined (Fig. 4).
Differences in FGF‑21 expression levels between the patient 
groups. The serum expression levels of FGF‑21 were signifi-
cantly higher among patients AoV stenosis compared with the 
control group (P<0.0001; Fig. 5). The most significant differ-
ence was observed in the severe stenosis group (P=0.003); 
however, significant differences were also observed in patients 
with moderate (P=0.015) and mild (P=0.013) stenosis groups 
compared with the control group (Fig. 6). The increase of 
FGF‑21 serum level (depending on the degree of AoV stenosis), 
in difference to chemerin, gradually increased, exhibiting a 
linear tendency, which is presented in Fig. 7 as positive slope 
of regression. A positive association was observed between 
the expression of chemerin and FGF‑21 in the control group 
(rp=0.34; P=0.019), and the aortic valve stenosis group (rp=0.35; 
P=0.012) (Fig. 8A and B). An increase in the chemerin level was 
associated with an increase in FGF‑21 concentration. A posi-
tive correlation between chemerin expression and serum levels 
of MMP‑9 was also detected (Fig. 8C; rp=0.362; P=0.008); 
however, no association between chemerin and high‑density 
lipoproteins (HDL) was identified.
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Differences in the serum levels of MMPs in patients with 
different degrees of aortic valve stenosis. The expression of 
MMP‑1 was also significantly increased in patients with AoV 
stenosis compared with the control group (P=0.0043). However, 
the results and their distribution were different from those 
obtained with chemerin and FGF‑21. It was also demonstrated 
that patients with aortic valve stenosis exhibited a dual distribu-
tion of the response (Fig. 9A). Therefore, the values of MMP-1 
were divided into two groups (including control subjects). In 
order to determine more precisely the differences between 
the control and stenosis groups, distribution analysis was 
performed (Fig. 9B) and it was demonstrated that the distribu-
tion of MMP-1 was trimodal in the aortic stenosis group and 
monomodal in the control group. A total of 80% of patients in 
the aortic stenosis group (marked with a green oval) exhibited 
a significantly increased MMP‑1 expression level compared 
with the control group (P=0.0001; Fig. 9C); however, MMP‑1 
Figure 6. Serum FGF‑21 expression level in the control group and in aortic 
valve stenosis groups with different grades of severity. FGF‑21, fibroblast 
growth factor-21.
Figure 5. Serum FGF‑21 level in the control and AoV stenosis group.
Figure 4. Regression line of the serum chemerin level in connection with the 
AoV stenosis severity grade.Figure 1. Serum CRP level in the control group and among patients with different degrees of aortic valve stenosis severity. CRP, C‑reactive protein.
Figure 3. Serum Chemerin level in the control group and in AoV stenosis 
groups with different grades of severity.
Figure 2. Serum chemerin level in the control and aortic valve stenosis 
stenosis groups.
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expression levels remained unaltered for 20% of patients with 
aortic stenosis results compared with the control group. The 
highest MMP-1 expression level was observed in the moderate 
AoV stenosis group (P<0.0001) and the lowest level in the severe 
aortic stenosis group (P=0.012), compared with the control 
patients (Fig. 9D). Analyses of serum expression levels of 
MMP-3, MMP-9, TIMP-1 and TIMP-3 between patients with 
aortic valve stenosis and the control patients, did not reveal any 
statistically significant differences (Fig. 10). A positive correla-
tion was identified between MMP‑1 and MMP‑9 expression 
levels (rp=0.37; P=0.017; Fig. 11A); however, no associations 
were revealed between the expression levels of MMP-1 and 
MMP‑3 and TIMP‑1 (Fig. 11B and C).
Discussion 
The present study analyzed the role of MMP‑1 in the develop-
ment of acquired calcific AoV stenosis, and identified the highest 
serum MMP-1 level in the moderate AoV stenosis group. The 
results of previous studies investigating the association between 
MMP-1 an AoV stenosis, the results demonstrated increased 
MMP-1 levels in damaged aortic valves resulting in degradation 
of the extracellular matrix components, including interstitial 
collagen types I, II and III, destruction of collagen, osteoblast 
differentiation and calcification (7,15,28).
Solache‑Berrocal et al (28) studied the association between 
the MMP‑1 1G>2G polymorphism and parameters indicative 
of mineralization in aortic valves from valve replacement. 
The results obtained by Solache‑Berrocal et al confirmed the 
association between the highest amounts of calcium in valves 
with individuals carrying the allele resulting in increased 
transcription and translation of MMP-1. The association 
between 1G>2G MMP‑1 polymorphism and calcium content of 
the aortic valve suggests that the 1G allele may exhibit a protec-
tive effect against calcium deposits.
The current study analyzed the results of serum MMP‑1 
expression among patients with AoV stenosis divided into 
two subgroups. In the current study, 20% of patients with 
AoV stenosis did not exhibit increased serum MMP-1 levels 
compared with the control group. Further analysis of expression 
levels among these patients revealed that all patients exhibited 
mild AoV stenosis. We assume that this stratification of the 
results into two subgroups (especially in patients of mild and 
moderate stenosis), may be required to determine whether AoV 
stenosis progressed more slowly among these patients. Other 
factors possibly involved in the pathogenesis of AoV stenosis 
should be considered. Mohty with co‑authors (29) demonstrated 
that increased valvular oxLDL expression was associated 
with an increased tissue remodeling score, suggesting that 
oxLDL could be involved in the fibrocalcification of the aortic 
valve. The results of the current study and data from previous 
studies (8,9,12,13,15,28) lead to a hypothesis that the most 
pronounced extracellular matrix remodeling occurs among 
patients with moderate AoV stenosis as the serum level of 
MMP-1 increases starting from the mild stenosis grade, reaches 
the maximum level in patients with moderate AoV stenosis, 
and decreases slightly in patients with severe AoV stenosis. 
Alterations in serum levels of MMP-1 observed in the present 
study in patients with different AoV stenosis severity grades 
Figure 8. Regression analysis. Association analysis between serum chemerin 
and FGF‑21, and chemerin and HDL (A) in the control and (B) in the AoV 
stenosis group. (C) Association between chemerin and MMP-9 in the AoV 
stenosis group. AoV, aortic valve; FGF‑21, fibroblast growth factor‑21; 
HDL, high‑density lipoprotein.
Figure 7. Regression line of the serum FGF‑21 level and the aortic valve 
stenosis severity grade. FGF‑21, fibroblast growth factor‑21.
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correspond with the results of other studies (9,28) obtained using 
tissues and histological analyses. The lowest levels of MMP‑1 
were observed among patients with severe AoV stenosis, which 
may indicate low or absent inflammation at this stage of the 
disease and the development of valvular calcinosis.
In the present study, the serum expression level of TIMP‑1 
did not differ significantly between the control and AoV stenosis 
groups. Other authors have previously reported similar results. 
Kaden et al (9) studied the association between the inflammation 
in stenotic valves and the regulation of expression and activa-
tion of MMPs. It has been demonstrated that within lesions, 
leukocytes activated by the secretion of tumor necrosis factor‑α, 
may stimulate valvular myofibroblasts to proliferate and express 
MMP-1, while TIMP-1 remains unchanged (9). The expression 
of TIMP‑1 was individually variable in both stenotic and control 
valves, showing no statistically significant difference between 
the groups.
The current study did not identify a correlation between the 
serum levels of TIMP-1 and MMP-1, which meant that TIMP-1 
was excluded as a factor that causes an increase of MMP-1. 
Therefore, the upregulation of MMP‑1 may serve as an explana-
tion for the increased concentration of MMP-1 in patients with 
aortic stenosis, and this increase may be persistent and not regu-
lated by TIMP. The analysis of serum levels of MMP‑3 did not 
reveal a statistically significant difference between patients with 
AoV stenosis and the control group. Furthermore, the current 
study did not identify any significant differences between 
MMP-9 serum expression levels in patients with AoV stenosis 
and the control group patients. The above results indicate that 
the pathophysiological process in AoV stenosis is not the same 
Figure 9. MMP‑1 expression analysis. (A) Serum MMP‑1 level in the control and AoV stenosis groups, ovals in green and red represent AoV stenosis patient 
clusters of data. (B) Histograms of MMP‑1 distribution. Serum MMP‑1 level. Modes are represented by color circles. (C) Serum MMP‑1 levels in the control 
and AoV stenosis groups. Green ovals represent a cluster of 80% patients from (A)  (D) MMP‑1 serum level in control and in patients with different degrees of 
AoV severity. AoV, aortic valve; MMP‑1, matrix metalloproteinase‑1.
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as for atherosclerosis. Papazafiropoulou and Tentolouris (15) 
demonstrated that MMP-9 serves a central role in atheroscle-
rosis, plaque formation, platelet aggregation, acute coronary 
syndrome, restenosis, aortic aneurysms and peripheral vascular 
disease. Increased MMP‑9 levels are an independent risk factor 
of cardiovascular mortality among patients with coronary 
artery disease (16). The current study did not reveal an increase 
in MMP-9 serum levels in patients with aortic stenosis and did 
not identify an association between MMP‑9 and TIMP‑1 serum 
levels.
Satta et al (30) studied the expression of elastolytic MMPs 
and TIMPs in non‑rheumatic aortic stenosis. The study 
concluded that the disproportion between MMP-9 and its 
tissue inhibitors may favor persistent MMP activation state 
within the calcific valve and contribute to the valvular remod-
eling process in the developing aortic stenosis. Satta et al 
also reported that MMP‑9 protein was almost exclusively 
localized near or around the mineralized nodules, whereas the 
expression was generally weak or absent in areas devoid of 
calcification.
The current study did not identify any correlation between 
the serum levels of TIMP‑1 and MMP‑9; however, a positive 
correlation was identified between the serum level of MMP‑1 
and MMP‑9. The results of the current study were compared 
with those from previous studies involving histological mate-
rial (15,16,30) and based on these data, it was hypothesized that 
MMP‑9 functions more locally at cellular level. The results of 
the current study indicated that MMP‑1 may serve an important 
role in patients with aortic valve stenosis. Further studies on the 
role of MMPs in the development of AoV stenosis could result 
in clinical application of this knowledge.
The current study further analyzed the association between 
aortic valve stenosis and inflammatory factors including 
Figure 10. Serum levels of MMP‑3, MMP‑9, TIMP‑1 in the control and AoV 
stenosis groups. MMP, matrix metalloproteinase; TIMP, tissue inhibitor of 
metalloproteinase; AoV, aortic valve.
Figure 11. Regression analyses. Regression lines of serum (A) MMP‑1 and 
MMP‑9, (B) MMP‑1 and MMP‑3, and (C) MMP‑1 and TIMP‑1 in patients 
with AoV stenosis. AoV, aortic valve; MMP, matrix metalloproteinase.
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chemerin, C‑reactive protein and FGF‑21. Chemerin has been 
previously identified in different inflammatory and systemic 
processes (31,32); and, therefore, patients with systemic and 
inflammatory diseases were excluded from the current study. 
Regn et al (17) demonstrated that pro-chemerin was expressed 
and secreted by the cardiac fibroblasts and converted to 
bioactive chemerin during proteolytic process, substan-
tiating the idea that chemerin may exhibit both, pro‑ and 
anti‑inflammatory functions. Analyzing the level of chemerin 
among patients with AoV stenosis and in the control group, 
the current study demonstrated that the expression chemerin 
was significantly increased among patients with AoV stenosis. 
Further analysis of AoV stenosis subgroups revealed that the 
highest serum chemerin level was present in the mild AoV 
stenosis group and a progressive decrease of chemerin levels 
was observed with an increasing degree of stenosis. In the 
control group the chemerin expression level was significantly 
lower compared with patients with severe AoV stenosis. Since 
chemerin is an inflammatory factor (28), its reduction with the 
progression of aortic stenosis suggests that the inflammation 
is prevalent at the beginning of the disease; however, calci-
nosis may predominate at later stages. The C‑reactive protein 
expression results further supported the hypothesis that at the 
beginning of AoV stenosis the inflammatory prices may be 
prevalent, as the expression levels of this protein were signifi-
cantly increased in patients with mild stenosis compared with 
the control group. Galante et al (33) identified and described 
elevated C-reactive protein levels in degenerative aortic valve 
stenosis. The aforementioned results suggest that AoV stenosis 
at early stages may present as an active inflammatory process. 
At more severe stages, decreased serum chemerin levels 
suggest that extracellular matrix alterations and calcification 
may be the dominant processes in moderate and severe calcific 
AoV stenosis.
Chemerin has been studied as an inflammatory marker and 
FGF‑21 as a factor that could induce a protective effect on the 
cardiac muscle in case of damage (17,20). FGF‑21 has been 
demonstrated to be released from the rat cardiac endothelial 
cells in vitro (18). FGF‑21 was found to improve endothelial 
function, decrease oxidative stress and prevent endothelial cell 
apoptosis (18,19,20,21). FGF‑21 could serve as a biological 
marker of stress and damage to endothelial cells and may serve 
a physiological role in improving endothelial function (18). The 
expression of FGF‑21 was significantly higher in patients with 
AoV stenosis compared with controls and further increased in 
patients with severe stenosis. The expression levels of serum 
chemerin were positively correlated with the levels of FGF‑21. 
These results lead to a hypothesis that FGF‑21 may serve a 
protective role in the pathogenesis of calcific AoV stenosis, as at 
the initial stages of the disease, only a slight increase in plasma 
FGF‑21 was identified, while a greater increase was identified in 
patients with severe grade AoV stenosis. Previous studies further 
suggested that FGF‑21 may exhibit a cardio protective role in 
different cardiovascular diseases including atrial fibrillation, 
myocardial infarction, coronary artery disease, hypertension, 
and cardiac hypertrophy (19,20), supporting the results of the 
current study. FGF‑21 also serves a role in the development of 
connective tissue (21). Considering the multiple effects FGF‑21 
and the association with connective tissue formation, it may be 
hypothesized that the increase in FGF‑21 expression may be 
due to the progression of AoV stenosis and increased connective 
tissue formation.
The current data indicated that inflammation was dominant 
at the early, mild stage of AoV stenosis, the most pronounced 
extracellular matrix remodeling occurred in moderate AoV 
stenosis and calcification may have been the tominant process in 
severe calcific AoV stenosis. These results lead to a conclusion 
that aortic valve stenosis is an active inflammatory process 
which possibly could be delayed by therapeutic interventions.
To reduce the level of MMPs in patients with aortic valve 
stenosis, medications (including Nevibolol) that release nitric 
oxide (NO), could be prescribed, as NO inhibits MMPs produc-
tion by endothelial cells and smooth muscle cells (15). Oxidized 
low density lipoprotein cholesterol has been observed to increase 
and high‑density lipoprotein cholesterol to decrease the produc-
tion of MMP‑1 (34). This indicates that treatment of dyslipidemia 
remains necessary and may protect from the development of a 
more severe aortic stenosis. Since the elevated level of glucose 
induces the expression of MMP-1 and MMP-2 from endothelial 
cells and the expression of MMP-9 from macrophages, it is 
important to actively treat glucose metabolism disorders in order 
to ensure maximum possible normoglycemia (35). Based on the 
results of previous studies investigating the effects of drugs on 
MMP and TIMP levels, the adverse drugs include nitroglycerin 
(no long-acting nitrates have been studied, to the best of our 
knowledge), amlodipine and diltiazem, as well as ACE inhibi-
tors, since angiotensin II decreases MMP‑1 activity (36,37). In 
cardiology, ACE inhibitors are a widely used drug group, and, 
therefore, the prevalence of progressive aortic stenosis could be 
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